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out among our patients. Before being allocated into the study 
groups, the patients had undergone a course of dental treatment 
programs for three weeks in order to reduce the amount of super- 
imposed ental inflammation as mnch as possible. Thereafter, the 
patients were randomized into intervention and control groups. 
Metronidazole tablets 250 mg/TDS were given to the interven- 
tion group, while the control group received the same amount of 
placebo. Patients were examined by a blinded periodontologist, at 
clays 0, 7, 14, and 2 I, to determine the gingival overgrowth scores, 
Results: The two groups were identical in age, gender, cause of 
receiving cyclosporine (kidney or bone marrow transplantation), 
duration of receiving cyclosporine, plasma level of cyclosporine 
and gingival overgrowth scores. Gingival enlargement improved 
in 7 patients, of whom 6 were in our intervention group (54.5%). 
The response to reatment was different in two groups ignificant- 
ly (P= 0.03). No association was found between gender, cause of 
receiving cyclosporine, duration of receiving cyelosporine, plasma 
level of cyclosporine and gingival overgrowth scores variables and 
response to treatment. Conclusion: In conclusion, our findings 
suggest hat we can benefit the advantages of metronidazole 
administration i  CIGH. Mthough we think that higher doses of 
metronidazole in association with oral hygiene programs and den- 
tal treatment planning could show better esults in such patients. 
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RECOVERY OF LEUKOCYTES FROM CORD BLOOD UNITS AFTER CON- 
TROLLED RATE FREEZE IN DMSO AND CRYOPRESERVATION IN THE 
VAPOR PHASE OF LIQUID NITROGEN 
Latze, T.A.t; Buenviaje, J / ;  Phmkett, M/; Law, lO.2 1. Americmz Red 
C'ross fVestetvz Area Commu~ity Cord Blood Ba*zk, Pot'tla~M, OR; 
2. University of Califor*zia, Sa~z Diego, &'hool of 3iedieiTze, La ffolla, CA. 
American Red Cross, Western Area Community Cord Blood 
Bank has established a program to assure the quality of cryopre- 
served volunteer donor cord blood units (CBU). Recovery. (Rec) 
of leukocytes (WBC) and WBC viability after CBU thawing are 
important surrogate measures CBU quality. We determined tl~e 
Rec of WBC in cryopreserved CBU immediately post-thaw and 
after dilution and washing in Dextran 40/5% Albumin (D/A), 
which is widely employed. Methods: CBU were collected from 
consented volunteer donors. CBU that were eligible for trans- 
plant, but had less WBC than required by storage criteria (6 ES) 
were studied. CBU were processed within 48 hours by Rubin- 
stein's method. The CBU volume after addition of 10% DMSO 
was 25 ml. CBU were cryopreserved by controlled rate freezing 
and stored in vapor phase liquid nitrogen for up to I year. Twelve 
CBU selected for study were removed from storage and immedi- 
ately placed in a 37 C waterbath. After thawing, the CBU was 
maintained at 4 C and a sample was immediately removed to 
assess post-thaw WBC (% NC-Rec) and cell viability by Trypan 
blue dye exclusion (% TB-viable). The CBU was diluted over 2 
rain in 25 ml D/A, samples removed, then the CBU was diluted to 
100 ml in D/A. The CBU was centrifuged at 400 xG at 4 C and 
resuspended in 25 ml of D/A. WBC Rec and NC viability were 
assessed post-thaw, after the 1:1 dilution in D/A, and post wash 
and resuspension. I  separate experiments, the Rec of CD34-bear- 
ing cells was measured. Results: There was a median 22% loss of 
NC after thawing, and additional NC loss after dilution and wash 
ing. Post thaw trypan blue dye viability was slightly reduced. In 6 
separate xperiments he Rec of CD34+ cells was 107 + 31% after 
thawing and 106 -+ 33 after washing. Conclusions: Thawing of 
cryopreserved CBU was associatedwith loss of approximately 
22% of the total NC and reduction in overall cell viability. Fur- 
ther cell loss accompanied washing. Recovery of CD34 bearing 
cells was uperior to total NC. Hematopoietic progenitor growth 
in culture after CBU thawing was consistent with the above. 
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EX VIVO ENGINEERING OF PREVIOUSLY THAWED AND CRYOPRE- 
SERVED UMBILICAL CORD BLOOD (UCB) WITH INTERLEUKIN (IL)-2, 
IL-7, IL-12 AND ANTI-CD3 FOR EXPANSION OF CYTOTOXIC T LYM- 
PHOCYTES (CTL): PROMISING STRATEGY FOR ADOPTIVE CELLULAR 
IMMUNOTHERAPY (ACI) POST UCB TRANSPLANTATION(T) 
Cairo, M.S.; Ayello, J.; vat~ de Ven, C. Child'ren's Hospital ofNew 
York Presbyteriml, New York, NY. 
Limitations associated with using UCB as a source for ACI post 
UCBT includes the lack of donor immunoeffector cells from the 
original cryopreserved UCB unit and/or immaturity of CB cellular 
immunity. We have demonstrated that CTL can be selectively 
engineered and activated from fresh and cryopreserved and thawed 
(CT) aliquots of UCB (Robinson/Cairo et al, Exp Hem 30:245, 
2002). In this study we evaluated and compared the activation and 
NK and LAK cytotoxicity of UCB CTL  Thawed UCB aliquots 
were monocyte depleted (5 xl06 cells/ml) in serum-free (SF) AIM- 
V in 5% CO2 @ 37°C. Nonadherent cells (lxl06 cells/ml) were 
either cultured in SF AIM-V + anti-CD3 (50 ng/ml), IL-2 (5 
ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml) (AB/CY) or in SF 
AIM-V alone for 48 hours @ 37°C in 5% CO2 or expanded, recry- 
opreserved and rethawed (TECT), or not expanded but recryopre- 
served, rethawed and subsequently expanded (TCTE). NK subsets 
were analyzed by flow cytometry and NK and LAK cytotoxicity by 
YVST- 1 methodology utilizing a 10:1 E:T ratio against K562 (NK) 
and Dandi (LAK), respectively. A significant enhancement i  NK 
cytotoxicity was seen when UCB cells were cultured in the AB/CY 
cocktail (p<0.001) when compared to media alone, but no differ- 
ence between the nrodalities (TE: 0.73+0.03 vs 0.16-+0.01; 
TECT:0.72_+0.03 vs 0.16+_0.01 and TCTE:  0.75+0.04 vs 
0.16-+0.01). Similarly, there was significant enhancement of LAK 
cytotoxcity with all modalities of AB/CY stimulation vs media 
alone (p<0.001) but no difference between modality (TE: 0.39-+0.01 
vs 0.26-+0.0l; TECT: 0.37-+0.008 vs0.23+_0.002; TCTE: 0.41_+0.01 
vs 0.20-+0.01). Furthermore, there was a signfificant increase in the 
CD3-/16+/56+ subset of TE, TECT and TCTE when compared 
to media alone (TE: 60.2-+1.24% vs 47.33-+0.55%, n=3, p<0.001; 
TECT:  60.67+2.4% vs 46.68-+1.3%, n=3, p<0.001; TCTE:  
60.7+-3.27% vs 45.45_+1.4%, n=3, p<0.001). These data suggest that 
previously cryopreserved an  thawed UCB aliquots may be engi- 
neered at time of UCB transplant, ex vivo expanded and activated 
for cytotofic (NK & LAK) potential and recryopreserved for later 
use for DLI post UCBT. Xenotransplant animal studies are under- 
way to examine the in vivo effects of this UCB CTL population. 
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ONCE AND TWICE FILGRASTIM FOR ALLOGENEIC PBSC MOBILIZATION 
Yuji, I(.1; Hamaki, T.e; Iiji~la, K. 2, Yosihcma, S.2; Imataki, 0.2; Koji- 
ma, R.2; Ueymna, j.2; ~smni, E.e; Mmo, F.2; JliitaJd, 1(.2; Mori, S. e 
1. ToT:a*mmon Hospital, Minato-ku TOI~O, Japing; 2. Japa,z Hema- 
tology and 07~cology Clinical Study Group, Bu,~kyo-ku TOIxTO, ffapan. 
Objective: To compare fficacy and safety in allogeneic periph- 
eral blood stem cell (PBSC) donors who received 400gg/m^2/day 
of filgrastim administered sl~bcutaneously once daily (Once-daily 
regimen) or in two-divided ose every 12 hours (Twice-daily regi- 
men). Design: An open-label, randomized, multicenter phase III 
trial. Patients: Between May 2001 and May 2002, 72 PBSC 
donors were enrolled in this study. Eligibility criteria was as fol- 
lows: Allogeneic PBSC donors to related patients aged between 16 
and 65 years, eligible for the criteria described in the Japan Soci- 
ety for Hematopoietic Cell Transplantation (JSHCI) guideline of 
PBSC harvest. Intervention: Donors were randomly assigned to 
receive 400btg/m^2 of G-CSF (filgrastim) subcutaneously once 
daily or in two-divided doses every 12 hours on 3 consecutive 
d~ys. PBSC was collected by leukapheresis u ing COBE Spectra 
on day 4. Main Outcome Measures: The primary endpoint of this 
study was CD34 positive cell dose per kg of donor's body weight 
collected by leukapheresis on day 4. Additional endpoints were 
total nucleated cell (TNC) counts in the leukapheresis products, 
total pain burden experienced by donor measured with area under 
curve (AUC) of visual analogue scale (VAS), and total dose of 
analgesic drugs. Safety endpoints: Incidence and severity of 
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